Our objective was to evaluate an open-label. multicenter. single-arm study to appraise whether amrubicin therapy improves patients with refractory small-cell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. https://www.diegojavierfares.com/deal-time-Hybrid-Racing-V3-Short-Shifter-Assembly-02-06-RSX-K-Swap-flash-save/